Quitting smoking and psoriasis: fewer new diagnoses is not the same as clearer skin

01

What counted as a new case?

The 2024 Korean cohort enrolled people initially without recorded psoriasis and compared smoking changes in 2004–2007 with diagnoses during later follow-up, through 2021. Its quitter-versus-continuing-smoker estimate for overall psoriasis was an adjusted hazard ratio of 0.91, with a 95% confidence interval of 0.87–0.95. This is a comparison between groups, not a skin-treatment trial.

In the newer study, published online in 2025 and in a 2026 journal issue, a case required at least three clinical visits carrying a relevant diagnosis code. The outcome was a newly recorded diagnosis, not the first biological change in the skin. Existing psoriasis had been excluded: plaque clearance, itch relief and treatment response were not the outcomes being tested.

[1][2]

02

Why the study comparisons cannot be turned into a countdown

In the comparison table, each HR compares the event rate at a given point in follow-up among people who have not yet had that event. It is not the cumulative probability of developing psoriasis. An interval that includes 1 does not establish a clear difference at the study's statistical threshold, but neither does it prove that the groups are identical.

The two Korean analyses overlap in their insurance-database population; they are not two independent replications. The US Women's Health Initiative analysis studied postmenopausal women and used Medicare-recorded psoriatic disease diagnoses. Its overall former-versus-current smoking comparison was not statistically significant, even though some narrower smoking-history subgroups were. Different populations, definitions and smoking windows cannot be pooled by reading headlines.

[1][2][4]

03

BMI change is not a condition you must satisfy before quitting

The newer Korean primary analysis found a lower overall-psoriasis hazard in quitters without an interval BMI change, but no clear difference in the BMI-gain group. The authors also analysed particular subtypes and differently selected follow-up samples; a favourable palmoplantar-pustulosis result cannot stand in for every psoriasis outcome.

Quitting and BMI change were both inferred between the same two examinations. The exact quit date was unavailable, so the weight change need not have followed quitting. The methodological letter also identifies unaccounted prior smoking burden and death as a competing event: someone who dies cannot receive a later recorded diagnosis. These are reasons to avoid a causal promise, not a reason to prescribe a weight target or keep smoking.

[2][3]

04

Keep the skin question and the support question separate

If you already have psoriasis, ask your GP or dermatologist about the disease itself; this incidence evidence cannot judge whether your own treatment is working. Bring new or changing concerns to the clinician responsible for your care rather than using smoke-free days as a test of recovery.

For help with stopping smoking in England, NHS Better Health explains local stop-smoking support. A useful question is: ‘Can you help me stop smoking while my skin condition is being assessed separately?’ That seeks support without promising what your skin will do.

[5][6]

05

What to keep in mind

• A new diagnosis is a different endpoint from improvement of existing lesions.
• Compare each smoking group with its stated reference, and retain the uncertainty.
• Skin care and smoking-cessation support are separate professional conversations.